Key result
Pentoxifylline exhibits antiproteinuric, antifibrotic, and anti-inflammatory effects that significantly reduce the risk of chronic kidney disease progression and cardiovascular complications.
Why the study?
Does pentoxifylline prevent the progression of renal dysfunction and cardiovascular diseases in patients with chronic kidney disease?
Does pentoxifylline prevent the progression of renal dysfunction and cardiovascular diseases in patients with chronic kidney disease?
Pentoxifylline is highlighted as a potentially effective and safe nephroprotective agent for preventing the progression of chronic kidney disease and associated cardiovascular risks.
Hypothesis-generating for pentoxifylline in CKD; prospective RCTs needed before clinical adoption.
Generalized data on nephroprotective efficacy of pentoxifylline in chronic kidney disease (CKD) are presented. The potential of this drug in treating people suffering from CKD and cardiovascular diseases (CVD) with a high risk of developing the terminal stage of renal dysfunction is considered. Antiproteinuric, antifibrotic and anti-inflammatory effects of pentoxifylline significantly reduce the risk of progression of CKD and joining of CVD in the future. Efficacy in preventing the onset of the uremic stage of CKD, safety andapplicability at all stages of renal dysfunction development make pentoxifylline a very appealing drug not only for nephrologists but also for physicians.
No takes yet. Share an insight, caveat, or question.
Муркамилов et al. (2019) conducted a review in Chronic kidney disease (CKD) and cardiovascular diseases (CVD). Pentoxifylline was evaluated. Pentoxifylline exhibits antiproteinuric, antifibrotic, and anti-inflammatory effects that significantly reduce the risk of chronic kidney disease progression and cardiovascular complications.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: